Drugs / Pimodivir
Pimodivir
also known as
JNJ63623872 · VX-787 · JNJ - 63623872 - ZCD · JNJ-872 · JNJ-872 HYDROCHLORIDE HEMIHYDRATE · PIMODIVIR HYDROCHLORIDE · Vx-787 anhydrous base
Trials 18
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 113 trials | ||||||
| Phase 1 | NCT03947814 | Jul 2019 → Sep 2020 | chronic renal failure syndrome | Janssen-Cilag International NV | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT03816631 | May 2019 → Apr 2020 | — | Janssen-Cilag International NV | Completed | No outcome recorded |
| Phase 1 | NCT03768609 | Dec 2018 → Mar 2019 | — | Janssen-Cilag International NV | Completed | No outcome recorded |
| Phase 1 | NCT03023852 | Feb → Apr 2017 | — | Janssen-Cilag International NV | Completed | No outcome recorded |
| Phase 1 | NCT02860806 | Aug 2016 → Jun 2017 | — | Janssen-Cilag International NV | Completed | No outcome recorded |
| Phase 1 | NCT02888327 | Jul 2016 → May 2017 | influenza | Alios Biopharma Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02658825 | Jan → Apr 2016 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT02659735 | Dec 2015 → Apr 2016 | influenza | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT02652650 | Dec 2015 → Jun 2016 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT02595268 | Nov 2015 → Jan 2016 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT02448004 | May → Jun 2015 | — | Janssen Cilag N.V./S.A. | Completed | No outcome recorded |
| Phase 1 | NCT02418559 | May → Jul 2015 | — | Janssen Infectious Diseases BVBA | Completed | No outcome recorded |
| Phase 1 | NCT02262715 | Jul → Oct 2014 | — | Janssen Infectious Diseases BVBA | Completed | No outcome recorded |
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT02532283 | Dec 2015 → Feb 2017 | influenza | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT01561807 | Mar → Oct 2012 | influenza | Vertex Pharmaceuticals Incorporated | Completed | Met primary |
| Phase 32 trials · 1 met primary · 1 missed | ||||||
| Phase 3 | NCT03381196 | Jan 2018 → May 2020 | influenza | Janssen Research & Development, LLC | Terminated | Met primary |
| Phase 3 | NCT03376321 | Jan 2018 → Mar 2020 | influenza | Janssen Research & Development, LLC | Terminated | Missed primary |
| Phase not stated1 trial | ||||||
| — | NCT03834376 | — | — | Janssen Research & Development, LLC | No longer available | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT02342249 Comparator | Dec 2014 → May 2016 | influenza | Janssen Research & Development, LLC | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2020-09-02 | Janssen Research & Development, LLC | Results Janssen to Discontinue Pimodivir Influenza Development Program jnj.com ↗
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that it has made a strategic decision to discontinue the development of pimodivir, an investigational antiviral treatment for influenza A infection. |
| 2013-03-04 | Vertex Pharmaceuticals Incorporated | Results VX-787 Showed Significant Antiviral Activity and Reduced the Severity and Duration of Influenza Symptoms in Phase 2 Challenge Study vrtx.com ↗
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that treatment with VX-787 in a Phase 2 influenza challenge study resulted in statistically significant improvements in viral and clinical measurements of infection. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-09-02 | Janssen Research & Development, LLC | Janssen to Discontinue Pimodivir Influenza Development Program jnj.com ↗ |
| 2014-06-18 | Vertex Pharmaceuticals Incorporated | Vertex Licenses VX-787 to Janssen Pharmaceuticals for the Treatment of Influenza vrtx.com ↗ |
| 2013-03-04 | Vertex Pharmaceuticals Incorporated | VX-787 Showed Significant Antiviral Activity and Reduced the Severity and Duration of Influenza Symptoms in Phase 2 Challenge Study vrtx.com ↗ |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 21 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pimodivir | “Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial.” PMID 30428049 ↗ Mar 20197“A Phase 2 Study of Pimodivir (JNJ-63623872) in Combination With Oseltamivir in” PMID 32604406 ↗ Aug 2022 |
| Known as | JNJ - 63623872 - ZCD | ChEMBL registry synonym — accepted as the source's own label CHEMBL3318007 ↗ |
| Known as | JNJ-872 | “The purpose of this study is to evaluate the effect of steady-state concentrations of JNJ-63623872 on the single-dose pharmacokinetics of pitavastatin in healthy participants....” NCT02595268 ↗ |
| Known as | JNJ-872 HYDROCHLORIDE HEMIHYDRATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3318007 ↗ |
| Known as | JNJ63623872 | “The purpose of this study is to assess the rate and extent of absorption of JNJ63623872 following administration of a single oral dose of 2\*300 milligram (mg) given as 2...” NCT03023852 ↗ |
| Known as | PIMODIVIR HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3318007 ↗ |
| Known as | VX-787 | “This open-label, four group, fixed-sequence study will evaluate the safety and pharmacokinetic interaction of AL-794 on oseltamivir, JNJ-63623872 (formerly VX-787) and probes...” NCT02888327 ↗ |
| Known as | Vx-787 anhydrous base | ChEMBL registry synonym — accepted as the source's own label CHEMBL3318007 ↗ |
| Action | Inhibit | “Pimodivir, a first-in-class inhibitor of influenza virus polymerase basic protein 2” PMID 30428049 ↗ Mar 2019 |
| Modality | Small molecule | — CHEMBL3318007 ↗ |
| Route | Oral | “taken orally for 5 days” NCT01561807 ↗ |